World News: 13:00 GMT Wednesday 12th June 2019. [BioCardia, Inc. via Globe Newswire via SPi World News]
SAN CARLOS, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the China National Intellectual Property Administration has recently issued the Company Patent No: ZL 2014 8 00125575 for “Target Site Selection, Entry and Update with Automatic Image Annotation,” with a term to January 7, 2034.
The patent describes the use of software that merges images from magnetic resonance imaging (MRI) or computed tomography (CT) with fluoroscopic imaging to plan, document and deliver cell, gene, protein and other therapies using interventional catheter systems. The image-guided technology is designed to enable real time tracking and measurement of therapy delivery, where practitioners can create delivery targets, change orientation, identify regions to avoid, and change course intra-procedure to optimize outcomes.
The Company has patents pending for image-guided technology in the U.S., Europe and Japan.
“We are enthusiastic about the potential of this technology to significantly enhance how therapy is delivered without adding procedure time,” said BioCardia CEO Peter Altman, PhD. “Working with a highly respected academic partner who has published groundbreaking work on this approach, we will focus on realizing the technology once we have an approved therapeutic product in CardiAMP™ cell therapy that will benefit from it.”
He continued, “We continue to see great promise in our unique approach based on enabling platform intellectual property that bridges the historical silos of biotherapeutics, medical devices, diagnostics and now, imaging, to benefit both patients and physicians.”
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on April 2, 2019, including under the caption titled “Risk Factors.” BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Globe Newswire: 13:00 GMT Wednesday 12th June 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.